Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T14:16:35.301Z.
Calculation as of: 2026-10-06T14:16:35.301Z.
Quote observation: 2026-10-06T14:15:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c1a6838803f42d6ea125a2cca62df7e150df7eb7d5f2d1fff74d5c1a91b3d340
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$471.69M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$468.85M
Price/OCF Ratio
193.98
TTM Avg
142.73
3Y Avg
100.92
5Y Avg
100.92
Market Cap
$465.75M
Price/OCF Ratio
N/A
TTM Avg
25.67
3Y Avg
25.67
5Y Avg
25.67
Market Cap
$451.27M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$449.79M
Price/OCF Ratio
20.40
TTM Avg
23.17
3Y Avg
204.78
5Y Avg
202.88
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | $474.79M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $474.23M | N/A | 5.46 | 5.49 | 10.64 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $471.69M | N/A | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $468.85M | 193.98 | 142.73 | 100.92 | 100.92 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $465.75M | N/A | 25.67 | 25.67 | 25.67 |
| NRC Health (NRC)vs › | $460.20M | 15.60 | 15.15 | 16.14 | 19.77 |
| Kamada Ltd. (KMDA)vs › | $458.67M | 12.74 | 15.89 | 21.03 | 20.03 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $451.27M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $449.79M | 20.40 | 23.17 | 204.78 | 202.88 |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.41M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
